Login to Your Account

Gilead's Phase III HBV Data: Viread Stacks Up To Hepsera

By Randall Osborne

Friday, June 8, 2007
Positive Phase III data with Gilead Sciences Inc.'s Viread for chronic hepatitis B virus didn't surprise Wall Street, and left analysts divided on whether marketing the compound - already prescribed off label - could threaten Hepsera further, the firm's already-cleared therapy, if approved for HBV. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription